SK Biopharmaceuticals Co., Ltd. (KRX:326030)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Pharmaceutical Business	706.74B	547.60B	354.89B	246.18B	418.64B
New Pharmaceutical Business Growth	29.06%	54.30%	44.16%	-41.20%	1510.23%
Total	706.74B	547.60B	354.89B	246.18B	418.64B
Total Growth	29.06%	54.30%	44.16%	-41.20%	1510.23%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Unallocated	-	-	-	-356.97B	-303.83B
United States of America	642.66B	438.66B	288.79B	388.21B	267.22B
United States of America Growth	46.50%	51.90%	-25.61%	45.28%	2114.91%
Korea	100.00M	6.01B	-	214.94B	455.25B
Korea Growth	-98.34%	-	-	-52.79%	-
Switzerland	33.25B	42.33B	12.77B	-	-
Switzerland Growth	-21.46%	231.41%	-	-	-
Cayman Islands	4.17B	35.84B	14.15B	-	-
Cayman Islands Growth	-88.35%	153.30%	-	-	-
Japan	12.91B	10.24B	12.77B	-	-
Japan Growth	26.06%	-19.80%	-	-	-
Malta	11.38B	12.26B	12.70B	-	-
Malta Growth	-7.17%	-3.50%	-	-	-
Other Countries	2.27B	2.25B	13.70B	-	-
Other Countries Growth	0.85%	-83.59%	-	-	-
Total	706.74B	547.60B	354.89B	246.18B	418.64B
Total Growth	29.06%	54.30%	44.16%	-41.20%	1510.23%

Source: S&P Global Market Intelligence.